Last reviewed · How we verify

Nicotine rescue method

VA Office of Research and Development · FDA-approved active Small molecule

Nicotine acts as an agonist at nicotinic acetylcholine receptors in the central and peripheral nervous system to reduce cravings and withdrawal symptoms in tobacco dependence.

Nicotine acts as an agonist at nicotinic acetylcholine receptors in the central and peripheral nervous system to reduce cravings and withdrawal symptoms in nicotine-dependent individuals. Used for Nicotine dependence and smoking cessation support.

At a glance

Generic nameNicotine rescue method
Also known asNicorette
SponsorVA Office of Research and Development
Drug classNicotinic acetylcholine receptor agonist
TargetNicotinic acetylcholine receptors (α4β2 and other subtypes)
ModalitySmall molecule
Therapeutic areaAddiction Medicine / Smoking Cessation
PhaseFDA-approved

Mechanism of action

Nicotine binds to nicotinic acetylcholine receptors, particularly those containing α4β2 subunits, which are upregulated in chronic smokers. By providing exogenous nicotine through non-combustible delivery methods (patches, gum, lozenges, nasal spray, or inhalers), the drug satisfies the brain's dependence on nicotine while avoiding the harmful effects of tobacco smoke, thereby reducing withdrawal symptoms and facilitating smoking cessation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: